New research suggests that individuals who stop using new GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who halt traditional diet and exercise plans.
Findings released in a prominent health publication demonstrates that while obese individuals frequently drop a large proportion of their total mass while undergoing treatment, the weight returns at an estimated rate of nearly a kilo each month after stopping.
"People using such drugs need to be cognizant of the danger of quick rebound weight gain when the treatment ends," stated expert Dr. Susan Jebb.
That rate of recovery means a return to original weight in about one and a half years.
Weighing Therapies
The research, which examined dozens of trials involving thousands of participants, contrasted the results of the injectable medications with other pills.
The team note that individuals who lose weight through diet and exercise usually experience a less rapid weight regain—approximately 0.1 kg a month—once they finish.
Understanding the Fast Regain
Experts suggest the way of the drugs accounts for the accelerated rebound.
GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.
"Sustained high doses of GLP-1 levels several times higher than the body's typical production might result in the system to generate a reduced amount of its own natural hormone, and may also lessen responsiveness to its actions," explained Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this medication leads to hunger is unsuppressed, making binge eating much more probable."
A Lifelong Issue?
The NHS suggest the injections for individuals with obesity-related medical conditions, alongside prescribed diet and exercise modifications.
A number of clinicians say that, considering the significant potential of weight regain, the treatment is often ongoing.
This view is supported by pharmaceutical companies, who state that the findings "underscore the chronic character of obesity," akin to managing diseases like hypertension.
Patient Testimonies
Individuals who have discontinued the medication explain a intense return of hunger.
"I experienced a switch that goes on and you're instantly extremely hungry," said an individual.
This difficulty is compounded if individuals have not developed lasting dietary or behavioural modifications during therapy.
Significant Interest
Survey data indicate that a significant number of people in the UK have tried these injections in the past year, with interest being substantial.
- Use is more common among females than men.
- The middle-aged demographic shows the greatest usage rates.
- Many access the medications through private healthcare rather than public health services.
In conclusion, experts stress that while GLP-1 drugs are effective tools for weight loss, they are not a magic fix and maintained weight loss hinges on ongoing behavioural management.
